Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Identifieur interne : 000542 ( Ncbi/Merge ); précédent : 000541; suivant : 000543Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Auteurs : Michel St-Hilaire [Canada] ; Eric Landry ; Daniel Lévesque ; Claude RouillardSource :
- Neurobiology of disease [ 0969-9961 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (drug effects), Corpus Striatum (metabolism), DNA-Binding Proteins (genetics), Denervation, Disease Models, Animal, Dopamine (metabolism), Dopamine Antagonists (pharmacology), Dynorphins (genetics), Enkephalins (genetics), Excitatory Amino Acid Transporter 2 (genetics), Gene Expression Regulation (drug effects), Gene Expression Regulation (physiology), Levodopa (pharmacology), Male, Neurons (drug effects), Neurons (metabolism), Neurotensin (genetics), Nuclear Receptor Subfamily 4, Group A, Member 1, Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinson Disease (metabolism), Phenotype, RNA, Messenger (drug effects), RNA, Messenger (metabolism), Rats, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear (genetics), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (metabolism), Receptors, Dopamine D3 (genetics), Receptors, Steroid (genetics), Transcription Factors (genetics), Tyrosine 3-Monooxygenase (drug effects), Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , drug effects : RNA, Messenger, Receptors, Dopamine D1, Tyrosine 3-Monooxygenase.
- chemical , genetics : DNA-Binding Proteins, Dynorphins, Enkephalins, Excitatory Amino Acid Transporter 2, Neurotensin, Receptors, Cytoplasmic and Nuclear, Receptors, Dopamine D3, Receptors, Steroid, Transcription Factors.
- drug effects : Corpus Striatum, Gene Expression Regulation, Neurons.
- drug therapy : Parkinson Disease.
- genetics : Parkinson Disease.
- metabolism : Corpus Striatum, Dopamine, Neurons, Parkinson Disease, RNA, Messenger, Receptors, Dopamine D1, Tyrosine 3-Monooxygenase.
- chemical , pharmacology : Dopamine Antagonists, Levodopa.
- physiology : Gene Expression Regulation.
- Animals, Denervation, Disease Models, Animal, Male, Nuclear Receptor Subfamily 4, Group A, Member 1, Phenotype, Rats, Rats, Sprague-Dawley.
Abstract
Motor complications induced through repeated L-DOPA treatment in patients with Parkinson's disease are thought to be the consequence of molecular adaptations that occur in response to repeated dopamine receptors stimulation. Here, we studied the molecular changes taking place in the denervated striatum of unilaterally 6-OHDA-lesioned rats repeatedly treated with L-DOPA alone or combined to the D1 receptor antagonist SCH23390. We looked at the territorial patterns of expression of neurotensin (NT), dynorphin (DYN), enkephalin (ENK) and Nur77 (also known as NGFI-B) mRNA expression in the striatum and contrasted these with markers of glutamatergic transport and dopaminergic receptor functions. The denervation process induced NT and Nur77 mRNA expression in ENK-positive cells. Subsequent repeated L-DOPA treatment led to a sensitization of L-DOPA-induced rotational response and produced a second surge of NT induction, this time limited to DYN-positive cells and preferentially restricted to the lateral striatum. In this specific territory, the number of Nur77-positive cells was decreased, in response to L-DOPA, when compared to the medial part of the lesioned striatum. L-DOPA treatment increased dopamine D3 receptor and glutamate transporter 1 (GLT1) mRNA expression in the lesioned striatum and that, specifically in an area overlapping one of Nur77 decrease and of NT/DYN induction. The concomitant administration of SCH23390 with repeated L-DOPA treatment blocked the development of behavioral sensitization and the appearance of all L-DOPA-induced molecular reorganizations reported above. Our results showed that repeated L-DOPA treatment produces, in a denervated striatum, a complex pattern of genes regulation in both the direct and the indirect striatal output pathways. This phenomenon is located preferentially in a striatal area receiving converging inputs from the thalamus and sensorimotor cortex and is dependent upon D1 receptor stimulation.
DOI: 10.1016/j.nbd.2005.04.001
PubMed: 15896973
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001226
- to stream PubMed, to step Curation: 001226
- to stream PubMed, to step Checkpoint: 001226
Links to Exploration step
pubmed:15896973Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.</title><author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name><affiliation wicri:level="1"><nlm:affiliation>Centre de recherche en Neuroscience, CHUL, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de recherche en Neuroscience, CHUL</wicri:regionArea><wicri:noRegion>CHUL</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Eric" sort="Landry, Eric" uniqKey="Landry E" first="Eric" last="Landry">Eric Landry</name></author><author><name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name></author><author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15896973</idno><idno type="pmid">15896973</idno><idno type="doi">10.1016/j.nbd.2005.04.001</idno><idno type="wicri:Area/PubMed/Corpus">001226</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001226</idno><idno type="wicri:Area/PubMed/Curation">001226</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001226</idno><idno type="wicri:Area/PubMed/Checkpoint">001226</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001226</idno><idno type="wicri:Area/Ncbi/Merge">000542</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.</title><author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name><affiliation wicri:level="1"><nlm:affiliation>Centre de recherche en Neuroscience, CHUL, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de recherche en Neuroscience, CHUL</wicri:regionArea><wicri:noRegion>CHUL</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Eric" sort="Landry, Eric" uniqKey="Landry E" first="Eric" last="Landry">Eric Landry</name></author><author><name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name></author><author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="ISSN">0969-9961</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>DNA-Binding Proteins (genetics)</term><term>Denervation</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Antagonists (pharmacology)</term><term>Dynorphins (genetics)</term><term>Enkephalins (genetics)</term><term>Excitatory Amino Acid Transporter 2 (genetics)</term><term>Gene Expression Regulation (drug effects)</term><term>Gene Expression Regulation (physiology)</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Neurons (drug effects)</term><term>Neurons (metabolism)</term><term>Neurotensin (genetics)</term><term>Nuclear Receptor Subfamily 4, Group A, Member 1</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Phenotype</term><term>RNA, Messenger (drug effects)</term><term>RNA, Messenger (metabolism)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Receptors, Cytoplasmic and Nuclear (genetics)</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (metabolism)</term><term>Receptors, Dopamine D3 (genetics)</term><term>Receptors, Steroid (genetics)</term><term>Transcription Factors (genetics)</term><term>Tyrosine 3-Monooxygenase (drug effects)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>RNA, Messenger</term><term>Receptors, Dopamine D1</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA-Binding Proteins</term><term>Dynorphins</term><term>Enkephalins</term><term>Excitatory Amino Acid Transporter 2</term><term>Neurotensin</term><term>Receptors, Cytoplasmic and Nuclear</term><term>Receptors, Dopamine D3</term><term>Receptors, Steroid</term><term>Transcription Factors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Gene Expression Regulation</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dopamine</term><term>Neurons</term><term>Parkinson Disease</term><term>RNA, Messenger</term><term>Receptors, Dopamine D1</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Gene Expression Regulation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Denervation</term><term>Disease Models, Animal</term><term>Male</term><term>Nuclear Receptor Subfamily 4, Group A, Member 1</term><term>Phenotype</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor complications induced through repeated L-DOPA treatment in patients with Parkinson's disease are thought to be the consequence of molecular adaptations that occur in response to repeated dopamine receptors stimulation. Here, we studied the molecular changes taking place in the denervated striatum of unilaterally 6-OHDA-lesioned rats repeatedly treated with L-DOPA alone or combined to the D1 receptor antagonist SCH23390. We looked at the territorial patterns of expression of neurotensin (NT), dynorphin (DYN), enkephalin (ENK) and Nur77 (also known as NGFI-B) mRNA expression in the striatum and contrasted these with markers of glutamatergic transport and dopaminergic receptor functions. The denervation process induced NT and Nur77 mRNA expression in ENK-positive cells. Subsequent repeated L-DOPA treatment led to a sensitization of L-DOPA-induced rotational response and produced a second surge of NT induction, this time limited to DYN-positive cells and preferentially restricted to the lateral striatum. In this specific territory, the number of Nur77-positive cells was decreased, in response to L-DOPA, when compared to the medial part of the lesioned striatum. L-DOPA treatment increased dopamine D3 receptor and glutamate transporter 1 (GLT1) mRNA expression in the lesioned striatum and that, specifically in an area overlapping one of Nur77 decrease and of NT/DYN induction. The concomitant administration of SCH23390 with repeated L-DOPA treatment blocked the development of behavioral sensitization and the appearance of all L-DOPA-induced molecular reorganizations reported above. Our results showed that repeated L-DOPA treatment produces, in a denervated striatum, a complex pattern of genes regulation in both the direct and the indirect striatal output pathways. This phenomenon is located preferentially in a striatal area receiving converging inputs from the thalamus and sensorimotor cortex and is dependent upon D1 receptor stimulation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15896973</PMID><DateCreated><Year>2005</Year><Month>10</Month><Day>24</Day></DateCreated><DateCompleted><Year>2006</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol. Dis.</ISOAbbreviation></Journal><ArticleTitle>Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.</ArticleTitle><Pagination><MedlinePgn>450-60</MedlinePgn></Pagination><Abstract><AbstractText>Motor complications induced through repeated L-DOPA treatment in patients with Parkinson's disease are thought to be the consequence of molecular adaptations that occur in response to repeated dopamine receptors stimulation. Here, we studied the molecular changes taking place in the denervated striatum of unilaterally 6-OHDA-lesioned rats repeatedly treated with L-DOPA alone or combined to the D1 receptor antagonist SCH23390. We looked at the territorial patterns of expression of neurotensin (NT), dynorphin (DYN), enkephalin (ENK) and Nur77 (also known as NGFI-B) mRNA expression in the striatum and contrasted these with markers of glutamatergic transport and dopaminergic receptor functions. The denervation process induced NT and Nur77 mRNA expression in ENK-positive cells. Subsequent repeated L-DOPA treatment led to a sensitization of L-DOPA-induced rotational response and produced a second surge of NT induction, this time limited to DYN-positive cells and preferentially restricted to the lateral striatum. In this specific territory, the number of Nur77-positive cells was decreased, in response to L-DOPA, when compared to the medial part of the lesioned striatum. L-DOPA treatment increased dopamine D3 receptor and glutamate transporter 1 (GLT1) mRNA expression in the lesioned striatum and that, specifically in an area overlapping one of Nur77 decrease and of NT/DYN induction. The concomitant administration of SCH23390 with repeated L-DOPA treatment blocked the development of behavioral sensitization and the appearance of all L-DOPA-induced molecular reorganizations reported above. Our results showed that repeated L-DOPA treatment produces, in a denervated striatum, a complex pattern of genes regulation in both the direct and the indirect striatal output pathways. This phenomenon is located preferentially in a striatal area receiving converging inputs from the thalamus and sensorimotor cortex and is dependent upon D1 receptor stimulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>St-Hilaire</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre de recherche en Neuroscience, CHUL, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lévesque</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rouillard</LastName><ForeName>Claude</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004745">Enkephalins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027342">Excitatory Amino Acid Transporter 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539820">Nr4a1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011987">Receptors, Steroid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>39379-15-2</RegistryNumber><NameOfSubstance UI="D009496">Neurotensin</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>74913-18-1</RegistryNumber><NameOfSubstance UI="D004399">Dynorphins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004399" MajorTopicYN="N">Dynorphins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004745" MajorTopicYN="N">Enkephalins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027342" MajorTopicYN="N">Excitatory Amino Acid Transporter 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009496" MajorTopicYN="N">Neurotensin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057105" MajorTopicYN="N">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011987" MajorTopicYN="N">Receptors, Steroid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15896973</ArticleId><ArticleId IdType="pii">S0969-9961(05)00112-9</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2005.04.001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Landry, Eric" sort="Landry, Eric" uniqKey="Landry E" first="Eric" last="Landry">Eric Landry</name><name sortKey="Levesque, Daniel" sort="Levesque, Daniel" uniqKey="Levesque D" first="Daniel" last="Lévesque">Daniel Lévesque</name><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name></noCountry><country name="Canada"><noRegion><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000542 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000542 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15896973
|texte= Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15896973" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |